Shiva Arami is a Rheumatology/Immunology physician affiliated with University of Illinois Chicago. OpenAlex indexes 34 publications with 1,289 citations (h-index 18).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1740 W Taylor St
Chicago, IL 606127232
Telephone
866-600-2273Registry record last updated 23 Jun 2008.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20251 payment
- PFIZER INC.Program year20251 payment
- GlaxoSmithKline, LLC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
32.3%TNF inhibitor12.3%Humira(Cf) Pen33%Humira Pen22%Enbrel13%Enbrel Sureclick12%Humira7%Humira(Cf)7%Simponi6%Part D<11 patientsFolate Analog Metabolic Inhibitor12.2%Methotrexate100%Part D≥43 patients+ 7 more classes in this area
Nervous system
23.6%Opioid Agonist7.7%Tramadol Hcl100%Part D≥20 patientsGabapentinoids7%Gabapentin68%Pregabalin32%Part D<11 patients+ 4 more classes in this area
Metabolism & gastrointestinal
16.1%Corticosteroid11.8%Prednisone100%Part D≥49 patientsAminosalicylate2%Sulfasalazine Dr100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Tofacitinib repairs inflammation and mitochondrial dysregulation in GM-CSF-reprogrammed RA macrophages
Cellular and Molecular Immunology
2026 - Metabolic reprogramming by Syntenin-1 directs RA FLS and endothelial cell-mediated inflammation and angiogenesis
Cellular and Molecular Immunology
2023 - Syntenin-1-mediated arthritogenicity is advanced by reprogramming RA metabolic macrophages and Th1 cells
Annals of the Rheumatic Diseases
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Jerry Krishnan, MD
University of Illinois Chicago
John Daugirdas, MD
University of Illinois Chicago
Itishree Trivedi, MD
University of Illinois Chicago
Victor Gordeuk, MD
University of Illinois Chicago
David Felson, MD
Boston University
Marc Hochberg, MD
University of Maryland School of Medicine
Philip Mease, MD
Michelle Petri, MD
Johns Hopkins University School of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”